### GENOMIC HEALTH INC

Form 4

October 06, 2005

## FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* Baker Bros. Capital (GP), LLC

2. Issuer Name and Ticker or Trading Symbol

GENOMIC HEALTH INC [GHDX]

5. Relationship of Reporting Person(s) to

Issuer

(Last)

(First)

(Middle)

3. Date of Earliest Transaction

(Month/Day/Year) 10/04/2005

(Check all applicable)

\_X\_\_ 10% Owner

\_ Other (specify

**OMB APPROVAL** 

3235-0287

January 31,

2005

0.5

**OMB** 

Number:

Expires:

response...

Estimated average

burden hours per

667 MADISON AVENUE, 17TH **FLOOR** 

(Street)

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

Director

Officer (give title

Form filed by One Reporting Person X Form filed by More than One Reporting

below)

NEW YORK, NY 10021

| (City)                               | (State)                                 | (Zip) Tab   | ole I - Non-                           | Derivative S                            | Securi | ties Ac     | quired, Disposed   | of, or Benefi  | cially Owned  |
|--------------------------------------|---|---|--|---|--------|-------------|--|--|---|
| 1.Title of<br>Security<br>(Instr. 3) | 2. Transaction Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 3.<br>Transactic<br>Code<br>(Instr. 8) | 4. Securitie on(A) or Disp (Instr. 3, 4 | osed   | of (D)      | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Common<br>Stock                      | 10/04/2005                              |   | C                                      | 126,126                                 | A      | \$0         | 126,126 (1)  | I  | Through Partnerships (2)                              |
| Common<br>Stock                      | 10/04/2005                              |   | C                                      | 41,011                                  | A      | \$0         | 167,137 (1)  | I  | Through Partnerships (2)                              |
| Common<br>Stock                      | 10/04/2005                              |   | J                                      | 6,760 (3)                               | A      | \$ 0<br>(3) | 173,897 (1)  | I  | Through Partnerships (2)                              |
| Common<br>Stock                      | 10/04/2005                              |   | C                                      | 14,719                                  | A      | \$ 0        | 14,719 (1)   | I  | Through<br>Partnerships                               |

### Edgar Filing: GENOMIC HEALTH INC - Form 4

Common Stock J 595  $\underline{^{(5)}}$  A  $\underbrace{^{\$\,0}}_{(\underline{5})}$  15,314  $\underline{^{(1)}}$  I  $\underbrace{^{(4)}}_{\text{Partnerships}}$ 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4.<br>Transactic<br>Code<br>(Instr. 8) | 5. Number of ionDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |         | erivative Expiration Date (Month/Day/Yea cquired (A) or isposed of (D) nstr. 3, 4, and |                    | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |                                  |
|---|---|---|---|--|--|---------|--|--------------------|---|----------------------------------|
|   |   |   |   | Code V                                 | (A)  | (D)     | Date<br>Exercisable  | Expiration<br>Date | Title   | Amount or<br>Number of<br>Shares |
| Series B<br>Preferred                               | <u>(6)</u>  | 10/04/2005                              |   | C                                      |  | 378,378 | <u>(7)</u>   | (8)                | Common<br>Stock   | 126,126                          |
| Series E<br>Preferred                               | <u>(6)</u>  | 10/04/2005                              |   | С                                      |  | 123,035 | <u>(7)</u>   | (8)                | Common<br>Stock   | 41,011                           |
| Series E<br>Preferred                               | <u>(6)</u>  | 10/04/2005                              |   | C                                      |  | 44,159  | <u>(7)</u>   | (8)                | Common<br>Stock   | 14,719                           |

# **Reporting Owners**

| Reporting Owner Name / Address  | Relationships |           |         |       |  |  |  |
|---|---------------|-----------|---------|-------|--|--|--|
|   | Director      | 10% Owner | Officer | Other |  |  |  |
| Baker Bros. Capital (GP), LLC<br>667 MADISON AVENUE<br>17TH FLOOR<br>NEW YORK, NY 10021 |               | X         |         |       |  |  |  |
| BAKER JULIAN<br>667 MADISON AVENUE<br>17TH FLOOR<br>NEW YORK, NY 10021                  | X             | X         |         |       |  |  |  |

Reporting Owners 2

#### Edgar Filing: GENOMIC HEALTH INC - Form 4

### **Signatures**

| /s/ Julian C. Baker, | as Managing Member of Baker Bros. Capital (GP), |            |
|----------------------|---|------------|
| LLC                  |   | 10/05/2005 |
|                      | **Signature of Reporting Person                 | Date       |
| /s/ Julian C. Baker  |   | 10/05/2005 |
|                      | **Signature of Reporting Person                 | Date       |

# **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
  - In addition to Baker Bros. Capital (GP), LLC, this Form 4 is being filed jointly by Julian C. Baker, who has the same business address as Baker Bros. Capital (GP), LLC and may be deemed to have a pecuniary interest in securities owned by it. Because of certain relationships with other security holders of the Issuer, the Reporting Persons are filing solely for informational purposes as if they were a member of a
- (1) group of such shareholders. However, the Reporting Persons disclaim that they and any other person or persons, in fact constitute a "group" for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, or Rule 13d-5 thereunder or that they are the beneficial owners of such securities owned by any such person, and each of them disclaims beneficial ownership of securities reported herein except to the extent of their pecuniary interest, if any, therein.
- Represents securities owned by Baker Bros. Investments, L.P., a limited partnership of which the sole general partner is Baker Bros. (2) Capital, L.P., a limited partnership of which the sole general partner is Baker Bros. Capital (GP), LLC. Julian C. Baker is a controlling member of Baker Bros. Capital (GP), LLC.
- On September 8, 2005, the Issuer declared a conditional dividend of 791,210 shares of Common Stock to be distributed on a pro rata basis to the Issuer's stockholders of record at the commencement of the Issuer's initial public offering ("IPO") if the price per share of the Issuer's Common Stock sold in the IPO is \$11.40 or greater (the "Conditional Dividend"). As a result, the Reporting Persons received 6,760 shares of Common Stock as of October 4, 2005, the closing date of the IPO.
- Represents securities owned by Baker Bros. Investments II, L.P., a limited partnership of which the sole general partner is Baker Bros. (4) Capital, L.P., a limited partnership of which the sole general partner is Baker Bros. Capital (GP), LLC. Julian C. Baker is a controlling member of Baker Bros. Capital (GP), LLC.
- As a result of the Conditional Dividend, the Reporting Persons received 595 shares of Common Stock as of October 4, 2005, the closing date of the IPO.
- Every 3 shares of Preferred Stock were converted into 1 share of Common Stock upon consummation of the IPO. This conversion rate is reflected in the amount of securities underlying the derivative security reported in column 7.
- (7) These securities are exercisable immediately.
- (8) These securities do not have an expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3